Postmenopozal Stronsiyum Ranelat Tedavisinden Sonra Sıçan Kalp Dokusundaki Paraoksonaz ve Aril Esteraz Aktivitesindeki Değişiklikler

Abstract

AbstractAlterations on Paraoxonase and Aryl Esterase Activities in the Rat Heart Tissue After Postmenopausal Strontium Ranelate Therapy Objective: In this study, the effect of strontium ranelate which is used in treatment of postmenopausal syndromes enhancing the bone formation on paraoxonase and aryl esterase activities was investigated in the rats with osteoporosis. Method: 28 female Wistar albino rats were used to establish experimental osteoporosis model. Experimental animals were divided into 4 groups. Each group was composed of 7 rats. The group 1 was defined as “control group”. Group 2 was the one received strontium ranelate. Group 3 underwent ovariectomy operation and did not receive any drug. Group 4 was treated with strontium ranelate for three months after three months from the ovariectomy operation. Heart tissues of the animals in each group were isolated. Paraoxonase and aryl esterase activities were investigated. The data were statistically analyzed by utilizing SPSS 16.0 and ANOVA Test. Results: In this study, paraoxonase and aryl esterase activities in groups 2, 3 and 4 were found to be lower in comparison to that of the control group (p<0.05). Conclusion: The obtained data indicate that paraoxonase and aryl esterase levels in heart tissues get reduced during the postmenopausal period upon administration of strontium ranelate. In turn, this could make the organism sensitive to the cardiovascular diseases.

Keywords

• Paraoxonase, aryl esterase, strontium ranelate, osteoporosis, atherosclerosis

Postmenopozal Stronsiyum Ranelat Tedavisinden Sonra Sıçan Kalp Dokusundaki Paraoksonaz ve Aril Esteraz Aktivitesindeki Değişiklikler

Abstract

Türkçe Özet:Amaç: Bu çalışmada deneysel osteoporoz modeli oluşturulan sıçanlarda, kemik formasyonunu arttıran post-menopozal bir ilaç olan stronsiyum ranelatın kalp dokusundaki paraoksonaz ve aril esteraz enzim aktiviteleri üzerindeki etkileri incelenmiştir. Yöntem: Çalışmada 28 adet dişi Wistar albino sıçan kullanılmış ve her bir grupta 7 hayvan olacak şekilde 4 gruba ayrılmıştır. Bu gruplar kontrol grubu (grup 1), stronsiyum ranelat grubu (grup 2), overektomi grubu (grup 3) ve overektomi uygulandıktan 3 ay sonra 3 ay boyunca stronsiyum ranelat uygulanan grup (grup 4) olmak üzere tasarlanmıştır. Tüm gruplardaki hayvanların kalp dokuları izole edilmiş ve paraoksonaz ve aril esteraz enzim aktivitelerine bakılmıştır. İstatistiksel analiz için SPSS 16.0 ve ANOVA testi kullanılmıştır. Bulgular: Yapılan çalışmada gerek paraoksonaz gerekse aril esteraz enzim aktivitelerinin grup 2, grup 3 ve grup 4\'te kontrol grubuna kıyasla düşük olduğu tespit edildi (p<0.05). Sonuç: Bulunan sonuçlar post-menopozal dönemin ve stronsiyum ranelat kullanımının kalp paraoksonaz ve aril esteraz enzim aktivitelerini azalttığını ve organizmayı kalp damar hastalıklarına duyarlı hale getirebileceğini göstermektedir.

Keywords

• Paraoksonaz, aril esteraz, stronsiyum ranelat, osteoporoz, ateroskleroz

References

1. Tung S, Iqbal J. Evolution, aging, and osteoporosis. Ann N Y Acad Sci 2007;11162499—506.
2. Zhao H, Patrick Ross F. Mechanisms of osteoclastic secretion. Ann N Y Acad Sci 2007;11161238-44.
3. Crepaldi G, Romanato G, Tonin P, Maggi S. Osteoporosis and body composition. J Endocrinol Invest 2007;30:42—7.
4. Cashman KD. Diet, nutrition, and bone health. J Nutr 2007;137:2507—12.
5. Lindsay R. Prevention and treatment of osteoporosis. Lancet 1993;341:801-5.
6. Blahos J. Treatment and prevention of osteoporosis. Wien Med Wochenschr 2007;157:589—92.
7. Cole ZA, Dennison EM, Cooper C. Osteoporosis epidemiology update. Curr Rheumatol Rep 2008;10:92-6.
8. Nevitt MC. Epidemiology of osteoporosis. Rheum Dis Clin North Am 1994;20:535-59.

9. Sutherland WH, Manning PJ, de Jong SA, Allum AR, Jones SD, Williams SM. Hormone—replacement therapy increases serum paraoxonase arylesterase activity in diabetic postmenopausal women. Metabolism 2001;50:319—24.
10. Topçuoglu A, Uzun H, Aydin S, Kahraman N, Vehid S, Zeybek G, Topçuoglu D. The effect of hormone replacement therapy on oxidized low density lipoprotein levels and paraoxonase activity in postmenopausal women. Tohoku J Exp Med 2005;205:79—86.
11. Gupta G, Aronow WS. Treatment of postmenopausal osteoporosis. Compr Ther 2007;33:114-9.
12. Brochier ML, Arwidson P. Coronary heart disease risk factors in women. Eur Heart J 1998;19:45-52.
13. Toumis S. Improvement in bone strength parameters. The
14. role of strontium ranelate. J Mnsenloskelet Neuronal
15. Reginster JY, Sarlet N, Lejeune E, Leonori L. Strontium
16. ranelate: a new treatment for postmenopausal osteoporosis
17. Akçay YD, Sagin FG, Sendağ F, Oztekin K, Sozmen EY.
18. Effects of estrogen-only therapy on LDL oxidation in
19. Zago V, Sanguinetti S, Brites F, Berg G, Verona J, Basilio
20. F, Wikinski R, Schreier L. Impaired high density
21. Kwok S, Selby PL, McElduff P, Laing l, Mackness B,
22. Mackness Ml, Prais H, Morgan J, Yates AP, Durrington
23. Fenkci IV, Serteser M, Fenkci S, Akyol AM. Effects of
24. intranasal estradiol treatment on serum paraoxonase and
25. Aviram M, Rosenblat M, Bisgaier CL, Newton RS, Primo—
26. Parmo SL, La Du BN. Paraoxonase inhibits high-density
27. Costa LG, Vitalone A, Cole TB, Furlong CE. Modulation
28. of paraoxonase (PON1) activity. Biochem Pharmacol
29. Eckerson HW, Wyte CM, La Du BN. The human serum
30. paraoxonase/arylesterase polymorphism. Am J Hum Genet
31. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein
32. measurement with the Folin phenol reagent. J Biol Chem
33. Kumru S, Aydin S, Aras A, Gursu MF, Gulcu F. Effects of
34. surgical menopause and estrogen replacement therapy on
35. Ercal N, Gurer—Orhan H, Aykin—Burns N. Toxic metals and
36. oxidative stress part I: mechanisms involved in metal— induced oxidative damage. Curr Top Med Chem 2001;1z529—39.
37. Verit FF, Celik H, Yazgan P, Erel O, Geyikli I. Paraoxonase—
38. Bin Ali A, Zhang Q, Lim YK, Fang D, Retnam L, Lim SK.
39. Expression of major HDL-associated antioxidant PON-l is gender dependent and regulated during inşammation. Free Radie Biol Med 2003;34:824—9.
40. Oh HY, Kim SS, Chung HY, Yoon S. Isoşavone
41. supplements exert hormonal and antioxidant effects in postmenopausal Korean women with diabetic retinopathy. J Med Food 2005;8:1—7.